Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TNXP vs PTN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–6 Matrix Metrics)

PTN Overall Winner 6-Pillar Tally: TNXP 2 – 4 PTN Matrix Metrics: TNXP 6 – 4 PTN

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Tonix Pharmaceuticals Holding Corp. (TNXP) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). TNXP carries a Unified Composite Score of 42.6/100 (HOLD) at $2.88 (N/M Forward P/E, -436.2% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin).

  • Composite vs. Pillar Nuance: While TNXP currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. -436.2% operating margin) and revenue trajectory (-80.1% vs. +423.8% YoY).
  • Technical & Structure Timing Caution: TNXP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 10.8); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TNXP vs PTN
TNXP NASDAQ
Tonix Pharmaceuticals Holding Corp.
Pharmaceutical Preparations
$2.88
-4.32% 1D
Market Cap $58.5M
TTM Revenue $43M
Forward P/E N/M
Beta / 30D Vol 1.73β · 76% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 44.0 Flow 66.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.6%), weak momentum, RSI 11
RSI-14: 10.8 · SMA20: $4.72 · SMA50: $7.51
PTN US Equity Head-to-Head Winner
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07

6-Pillar Scorecard Institutional Category Breakdown (TNXP 2 – 4 PTN)

Columns: Metric · TNXP · PTN
1. Valuation Multiples PTN
Forward P/E N/M 42.9x
Trailing P/E N/M 42.9x
PEG Ratio N/M 1.62x
EV / Revenue N/M 0.1x
2. Growth & Scale TNXP
Revenue Growth (YoY) +423.8% -80.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $43M $13M
Market Cap $58.5M $11.1M
3. Profitability & Quality TNXP
Gross Margin 89.3% 6.2%
Operating Margin -436.2% -65.7%
Net Profit Margin 0.0% -63.5%
Return on Equity (ROE) -84.1% -877.5%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$185M EBITDA -$15M
Cash Flow Margin N/A -113.6%
Net Cash / Leverage $162M Net Cash $9.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PTN
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 82.4% (21st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity N/A 71.9% of Rev ($9.5M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TNXP (6) vs PTN (4)
Institutional Metric TNXP PTN Criterion Row Edge
Market Capitalization
Scale
$58.5M $11.1M Larger Scale TNXP
Trailing P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Forward P/E Ratio
Valuation
N/M 42.9x Lower Multiple PTN
Revenue Growth (YoY)
Growth
+423.8% -80.1% Higher Growth TNXP
Operating Margin (TTM)
Profitability
-436.2% -65.7% Higher Margin PTN
Net Profit Margin
Profitability
0.0% -63.5% Higher Margin TNXP
Return on Equity (ROE)
Capital Efficiency
-84.1% -877.5% Higher ROE TNXP
52-Week Range Position
Momentum
0% ($3–$21) 6% ($5–$31) Stronger Trend PTN
Beta / 30D Volatility
Risk Regime
1.73β · 76% Vol 0.87β · 106% Vol Lower Realized Risk TNXP
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite TNXP
Trailing 12M Revenue (USD)
Operating Scale
$43M $13M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
89.3% 6.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.62x PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$185M EBITDA ($162M Net Cash) -$15M ($9.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTN +54.06 pp
TNXP: -52.32% · PTN: +1.74%
3M Horizon PTN +35.53 pp
TNXP: -77.25% · PTN: -41.72%
6M Horizon PTN +19.99 pp
TNXP: -79.8% · PTN: -59.81%
1Y Horizon PTN +38.88 pp
TNXP: -82.17% · PTN: -43.29%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period TNXP Revenue PTN Revenue TNXP Op. Margin PTN Op. Margin Margin Leader
FY2018 N/A $70M N/A 38.6% PTN
FY2019 N/A $60M N/A 59.3% PTN
FY2020 N/A $0M N/A -20007.6% PTN
FY2022 N/A $0M N/A -2491.6% PTN
FY2023 $10M $0M -1523.9% -668.7% PTN
FY2024 $10M $0M -1354.3% -501.0% PTN
FY2025 $10M N/A -959.1% N/A TNXP
FY2026 N/A $10M N/A -65.7% PTN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TNXP BREAKDOWN
54d in phase · OBV DISTRIBUTION
Current IV 82.4%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact TNXP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TNXP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $58.5M market capitalization and -436.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published

Investor FAQ TNXP vs PTN Key Questions & Quantitative Answers

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Tonix Pharmaceuticals Holding Corp. (TNXP) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). TNXP carries a Unified Composite Score of 42.6/100 (HOLD) at $2.88 (N/M Forward P/E, -436.2% operating margin), whereas PTN carries 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin). Composite vs. Pillar Nuance: While TNXP currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (4–6 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. -436.2% operating margin) and revenue trajectory (-80.1% vs. +423.8% YoY). Technical & Structure Timing Caution: TNXP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 10.8); meanwhile PTN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TNXP leads the Growth & Scale pillar: TNXP posts +423.8% YoY revenue growth and +0.0% YoY earnings growth on $43M TTM revenue (89.3% gross margin, -436.2% operating margin), compared with PTN at -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2026), TNXP cumulative revenue shifted +0.0% while PTN shifted -85.7%. In operating R&D and SG&A reinvestment, TNXP deploys N/A (0 90-day corporate R&D disclosures) versus 71.9% of Rev ($9.5M) (0 disclosures) for PTN.

PTN screens cheaper on headline valuation multiples. TNXP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TNXP (-84.1% ROE) versus PTN (-877.5% ROE) capital efficiency.

In options market volatility and institutional positioning, TNXP carries 82.4% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.73β · 76% Vol realized risk). By comparison, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.